Fifth Third Bancorp Blueprint Medicines Corp Transaction History

Fifth Third Bancorp

$26.1 Billion
Q2 2024

A detailed history of Fifth Third Bancorp transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Fifth Third Bancorp holds 1,000 shares of BPMC stock, worth $92,460. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,000

Previous 1,000 -0.0%

Holding current value

$92,460

Previous $94,000 13.83%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 19, 2022	SELL	$54.1 - $110.08 $3,841 - $7,815	-71 Reduced 6.63%	1,000 $64,000
Q4 2021 Feb 01, 2022	SELL	$94.25 - $115.99 $6,409 - $7,887	-68 Reduced 5.97%	1,071 $115,000
Q3 2021 Oct 15, 2021	SELL	$80.98 - $109.47 $4,291 - $5,801	-53 Reduced 4.45%	1,139 $117,000
Q2 2021 Aug 06, 2021	SELL	$82.78 - $101.0 $7,532 - $9,191	-91 Reduced 7.09%	1,192 $105,000
Q1 2021 May 07, 2021	SELL	$90.71 - $108.28 $14,604 - $17,433	-161 Reduced 11.15%	1,283 $125,000
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $245,024 - $331,241	-2,661 Reduced 64.82%	1,444 $162,000
Q3 2020 Nov 09, 2020	SELL	$66.45 - $92.7 $45,518 - $63,499	-685 Reduced 14.3%	4,105 $381,000
Q2 2020 Aug 05, 2020	BUY	$57.09 - $79.27 $273,461 - $379,703	4,790 New	4,790 $374,000
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $3,736 - $6,089	-82 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $4,182 - $5,560	-71 Reduced 46.41%	82 $6,000
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $32,901 - $46,191	-523 Reduced 77.37%	153 $12,000
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $28,642 - $47,096	676	676 $47,000

Others Institutions Holding BPMC

# of Institutions

340

Shares Held

62M

Call Options Held

987K

Put Options Held

578K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.52B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.

Account

Fifth Third Bancorp Blueprint Medicines Corp Transaction History